Treatment of venous thromboembolism in cancer patients is specific and has been validated in trials that favor the use of LMWH (Low Molecular Weight Heparin) instead of VKA (Vitamin K Antagonist) treatment during 6 months. International recommendations have diffused this option.It is necessary to evaluate the compliance of physicians to this treatment by measuring the number of patients with cancer treated with long term use of LMWH.
Study Type
OBSERVATIONAL
Enrollment
502
proportion of patients treated for evolutive VTE according to international recommendations
Evaluation of the adherence to recommendations of VTE treatment in cancer patients
Proportion of patients treated for evolutive VTE according to international recommandations Patients could be hospitalised or could be out patient
Time frame: At baseline (J0)
Evaluation of VTE disease according to cancer diagnosis (proportion of SVT (Superficial Venous Thrombosis), DVT (Deep Venous Thrombosis), PE (Pulmonary Embolism)
Percentage of VTE (PE,DVT,SVT)and cancer type
Time frame: At baseline (J0)
Proportion of asymptomatic VTE disease for this population
percentage of VTE and cancer status (local, metastatic)
Time frame: At baseline (J0)
Feasibility of self injections for VTE treatment in cancer patients.
percentage of patients practising self injections
Time frame: At baseline (J0)
Proportion of patients with catheter thrombosis
Percentage of patients receiving novel cancer therapies
Time frame: At baseline (J0)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
CHR Annecy
Annecy, France
Centre Hospitalier Victor Dupouy
Argenteuil, France
CH AUCH
Auch, France
CH Beauvais
Beauvais, France
Institut Bergonie
Bordeaux, France
CHU de Brest
Brest, France
CHU de Caen
Caen, France
Centre François Baclesse
Caen, France
CH Antoine Gayraud Cedex 9
Carcassonne, France
Clinique du Parc CASTELNAU LE LEZ
Castelnau-le-Lez, France
...and 39 more locations